Intermediate Uveitis: Protecting Your Vision
Understanding Intermediate Uveitis
Intermediate uveitis is a form of eye inflammation classified by the Standardization of Uveitis Nomenclature (SUN) system. It targets the vitreous cavity and the pars plana, a region near the front edge of the retina. Unlike anterior uveitis, which affects the front of the eye, intermediate uveitis occurs deeper inside the eye. It can be harder to detect without a thorough examination.
When no underlying cause is found, the condition is often called pars planitis. In other cases, the inflammation is linked to a systemic disease or infection that must also be treated.
The immune system plays a central role in intermediate uveitis. Research shows that a specific type of white blood cell, called a CD4+ T cell, becomes activated and targets tissues inside the eye. These activated cells cross the blood-ocular barrier, a protective boundary that normally shields the eye from immune activity. Once inside, they trigger an inflammatory cascade in the vitreous and surrounding structures.
Studies have found elevated levels of interleukin-6 (IL-6), an inflammatory signaling molecule, in the vitreous of patients with active disease. Emerging research also suggests that gut bacteria may play a role by activating immune cells through molecular mimicry. In this process, the immune system mistakes eye tissue for a foreign invader.
The hallmark of intermediate uveitis is vitritis, meaning visible inflammation within the vitreous gel. A retina specialist may observe characteristic findings during examination, including:
- Snowballs: clumps of inflammatory cells floating in the lower portion of the vitreous
- Snowbanks: bands of inflammatory material that collect along the pars plana, typically at the bottom of the eye
- Peripheral vasculitis: inflammation of small blood vessels at the edges of the retina
Who Is Affected and Risk Factors
Intermediate uveitis most commonly affects younger individuals between the ages of 15 and 40. It can also occur in children, where it may be more difficult to diagnose. Younger patients often do not report subtle vision changes. The incidence is approximately 1.5 per 100,000 person-years, with a prevalence of 4.0 per 100,000 persons (Northern California Epidemiology of Uveitis Study, AAO EyeWiki). Among children under age 16, intermediate uveitis accounts for 15 to 33 percent of all pediatric uveitis cases (AAO, 2023).
Several systemic conditions are linked to intermediate uveitis. Multiple sclerosis is one of the most important associations. Between 7 and 30 percent of intermediate uveitis patients eventually develop multiple sclerosis (AAO EyeWiki). Sarcoidosis, an inflammatory disease that can affect the lungs and other organs, is found in approximately 25 percent of cases (AAO EyeWiki). Other associated conditions include inflammatory bowel disease and certain autoimmune disorders.
In certain geographic regions, infections can trigger intermediate uveitis. Lyme disease, tuberculosis, and syphilis are among the infections a retina specialist may test for during the diagnostic workup. Smoking has been identified as a risk factor that increases the chance of developing uveitis in general. Vitamin D deficiency and certain medications, including some biologics and immune checkpoint inhibitors, have also been associated with uveitis.
Research has identified genetic markers that may increase susceptibility. Associations with HLA-DR2 and HLA-DR15, specific genes involved in immune function, have been observed in patients with intermediate uveitis. Having these genetic markers does not mean a person will develop the condition. However, they may increase the likelihood when combined with other risk factors.
Signs and Symptoms
Many patients with intermediate uveitis notice a gradual onset of floaters. These are often described as cobwebs, spots, or strands drifting across the field of vision. Blurred vision is another frequent complaint, particularly if swelling develops in the macula (the central part of the retina responsible for sharp vision). Some patients also experience mild sensitivity to light, known as photophobia.
In mild cases, patients may have no symptoms at all. The condition may be discovered during a routine eye examination. This is one reason regular eye exams are important, especially for individuals with known risk factors.
Children may not recognize or communicate changes in their vision. Parents and teachers should watch for indirect signs such as difficulty reading, squinting, covering one eye, or holding books closer than usual. A decline in academic performance can also be a clue. Because children tend to have more aggressive inflammation and higher complication risk, early detection is especially important.
Certain symptoms suggest a serious complication and require urgent evaluation. See a retina specialist or go to the emergency room immediately if you experience:
- Sudden severe vision loss, which may indicate vitreous hemorrhage (bleeding inside the eye)
- Severe eye pain with nausea, which could signal acute glaucoma (dangerous pressure buildup in the eye)
- A rapid worsening of previously stable vision, which may suggest progression of macular edema
- New flashes of light or a shadow or curtain effect over part of the visual field
Diagnosis and Testing
Diagnosing intermediate uveitis begins with a thorough eye examination by a retina specialist. The doctor uses a slit lamp, a specialized microscope, to examine the front and back of the eye. Dilated fundus examination allows the specialist to look for snowballs, snowbanks, and signs of peripheral vasculitis. The degree of vitritis is graded on a standardized scale to guide treatment decisions.
Several imaging techniques help evaluate the extent of inflammation and detect complications. Optical coherence tomography (OCT) provides cross-sectional images of the retina to identify cystoid macular edema (CME). CME is a common complication in which fluid-filled pockets form in the macula. Fluorescein angiography, a test using injected dye, can reveal leakage, peripheral vasculitis, and areas of poor blood flow.
Because intermediate uveitis can be associated with systemic diseases and infections, a retina specialist may order blood tests and other studies. Common tests include chest imaging for sarcoidosis or tuberculosis, blood tests for Lyme disease and syphilis, and brain MRI if multiple sclerosis is suspected. Identifying a systemic cause is critical because treating the underlying condition often helps control the eye inflammation.
Treatment Options
Treatment of intermediate uveitis follows a stepladder strategy. It starts with the least aggressive options and escalates based on disease severity and response. The goal is to control inflammation, prevent complications, and minimize medication side effects. A retina specialist tailors the treatment plan to each patient based on the severity of inflammation, whether one or both eyes are affected, and any underlying systemic condition.
Corticosteroids are the first line of treatment for most patients with intermediate uveitis. For mild inflammation, topical steroid eye drops may be sufficient, particularly in patients who have already had cataract surgery. When stronger treatment is needed, a retina specialist may administer a periocular injection (steroid placed around the eye) or an intravitreal injection (steroid placed directly inside the eye).
Systemic corticosteroids, usually oral prednisone, are used for moderate to severe disease or when both eyes are affected. While effective at controlling inflammation quickly, long-term systemic steroid use carries risks. These include weight gain, elevated blood sugar, bone thinning, and mood changes.
For patients who need sustained local treatment, several implantable steroid devices are available. Ozurdex (dexamethasone intravitreal implant) is FDA-approved for posterior segment inflammation and releases medication over several months. Retisert (fluocinolone acetonide 0.59 mg implant), approved in 2005, provides long-term steroid delivery. However, it carries a higher risk of elevated eye pressure and cataracts. Yutiq (fluocinolone acetonide 0.18 mg implant) is a newer, lower-dose option that may produce fewer side effects.
Xipere (triamcinolone acetonide injectable suspension) is delivered through a suprachoroidal injection. The medication is placed in a space between layers of the eye wall. This approach targets inflammation locally while potentially reducing some steroid-related side effects.
When corticosteroids cannot control the disease or cause unacceptable side effects, a retina specialist may recommend steroid-sparing immunosuppressive therapy. Antimetabolites such as methotrexate and mycophenolate mofetil are commonly used as first-line options. The FAST trial found that methotrexate was as effective as or superior to mycophenolate mofetil for controlling uveitis inflammation (FAST Trial, 2019).
These medications work by suppressing the overactive immune response driving the inflammation. They require regular blood monitoring to check for side effects affecting the liver, kidneys, or blood cell counts.
Adalimumab (Humira) became the first FDA-approved biologic therapy for noninfectious intermediate, posterior, and panuveitis in adults in June 2016. The VISUAL clinical trials established its effectiveness in reducing the risk of uveitis flares. Adalimumab works by blocking tumor necrosis factor-alpha (TNF-alpha), a key inflammatory signaling molecule.
Other biologic agents used off-label for refractory cases include infliximab, which also targets TNF-alpha, and tocilizumab, which blocks IL-6. Research into newer agents, including JAK inhibitors (Janus kinase inhibitors), is ongoing for patients who do not respond to existing therapies.
What to Expect
Intermediate uveitis often follows a chronic or relapsing course. Some patients experience a single episode that resolves with treatment. Others require ongoing therapy for years. The condition tends to be more persistent and challenging to manage in children. Regular follow-up visits with a retina specialist are essential for monitoring inflammation and catching complications early.
Cystoid macular edema is the most common vision-threatening complication. It occurs in approximately 40 percent of intermediate uveitis cases (SUN Working Group, AAO). Cataracts develop in 15 to 50 percent of patients, due to both the inflammation and the steroid medications used to treat it (AAO EyeWiki). Other potential complications include glaucoma, vitreous hemorrhage, epiretinal membrane formation, and retinal neovascularization (abnormal new blood vessel growth).
Patients receiving treatment for intermediate uveitis need regular examinations. These visits assess how well therapy is controlling inflammation and screen for medication side effects. OCT scans are frequently used to monitor for macular edema. Eye pressure is checked at each visit, especially for patients receiving steroid therapy. Those on immunosuppressive medications also need periodic blood tests.
Living with Intermediate Uveitis
Managing intermediate uveitis is often a long-term commitment. Patients should attend all scheduled follow-up appointments, even when the eye feels normal. Inflammation can quietly worsen without noticeable symptoms. Catching a flare early often leads to simpler, more effective treatment. Keeping a record of symptoms, medication schedules, and any new health changes helps the retina specialist make informed decisions.
Because intermediate uveitis is frequently associated with systemic conditions, patients may need to work with multiple specialists. A neurologist may be involved if multiple sclerosis is suspected. A pulmonologist or rheumatologist may help manage sarcoidosis. An infectious disease specialist may be consulted if an underlying infection is identified. Open communication between all treating physicians leads to the best outcomes.
Patients with intermediate uveitis should be aware that smoking may increase the risk of flares. Quitting smoking is recommended if applicable. Wearing sunglasses can help manage light sensitivity. Maintaining overall health through a balanced diet, regular exercise, and stress management may support immune system balance. Some research suggests that vitamin D levels may play a role, though patients should discuss supplementation with their physician.
When to See a Retina Specialist
Anyone experiencing persistent floaters, unexplained blurred vision, or light sensitivity should have an evaluation by an eye care professional. That provider can determine whether a referral to a retina specialist is appropriate. Individuals diagnosed with multiple sclerosis, sarcoidosis, or other associated systemic diseases should ask about screening for intermediate uveitis, even without eye symptoms.
Patients with known intermediate uveitis should seek immediate care from a retina specialist or go to the emergency room for certain warning signs. These include sudden severe vision loss, new flashes of light, a curtain or shadow across the vision, severe eye pain, or rapid worsening of previously stable symptoms. These signs may indicate serious complications that require prompt treatment to preserve vision.
Questions and Answers
Yes, intermediate uveitis frequently involves both eyes, though the severity may differ between them. In cases of pars planitis (the idiopathic form), bilateral involvement is common. A retina specialist will examine both eyes at every visit, even if only one eye seems affected. Inflammation can develop in the other eye over time.
Treatment duration varies widely depending on the individual case. Some patients achieve remission after several months of treatment, while others require therapy for years. The retina specialist gradually reduces medication when inflammation has been quiet for a sustained period. Stopping treatment too early can lead to a recurrence, so the tapering process is carefully managed.
Uveitis is classified by the primary location of inflammation inside the eye. Anterior uveitis affects the front of the eye, intermediate uveitis affects the vitreous and pars plana, and posterior uveitis affects the retina and choroid. Panuveitis involves all regions. A patient diagnosed with one type can sometimes develop inflammation in other areas over time. The SUN Working Group published updated classification criteria for 25 uveitis subtypes in 2021 to improve diagnostic consistency (SUN Working Group, 2021).
Children with intermediate uveitis often require closer monitoring and more proactive treatment. They tend to have more aggressive inflammation and face a higher risk of complications such as amblyopia (reduced vision from disuse during development). A retina specialist experienced in pediatric cases will work closely with the child's family. Care may also be coordinated with a pediatric rheumatologist if a systemic condition is involved. Treatment choices are similar to those for adults, though dosing is adjusted for weight and age.
No specific diet has been proven to treat or prevent intermediate uveitis. However, maintaining overall health may support the immune system. Emerging research into the gut microbiome suggests that intestinal bacteria may influence immune activity related to uveitis. This area is still under investigation. Avoiding smoking, staying physically active, and eating a nutrient-rich diet are general measures that may contribute to well-being. Patients should discuss any supplement use with their retina specialist before starting new regimens.